1. Home
  2. CRBU vs CYBN Comparison

CRBU vs CYBN Comparison

Compare CRBU & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBU
  • CYBN
  • Stock Information
  • Founded
  • CRBU 2011
  • CYBN 2019
  • Country
  • CRBU United States
  • CYBN Canada
  • Employees
  • CRBU N/A
  • CYBN N/A
  • Industry
  • CRBU Medicinal Chemicals and Botanical Products
  • CYBN Pharmaceuticals and Biotechnology
  • Sector
  • CRBU Health Care
  • CYBN Health Care
  • Exchange
  • CRBU Nasdaq
  • CYBN Nasdaq
  • Market Cap
  • CRBU 188.8M
  • CYBN 176.0M
  • IPO Year
  • CRBU 2021
  • CYBN N/A
  • Fundamental
  • Price
  • CRBU $1.93
  • CYBN $7.65
  • Analyst Decision
  • CRBU Strong Buy
  • CYBN Strong Buy
  • Analyst Count
  • CRBU 3
  • CYBN 3
  • Target Price
  • CRBU $6.67
  • CYBN $85.00
  • AVG Volume (30 Days)
  • CRBU 1.0M
  • CYBN 375.6K
  • Earning Date
  • CRBU 08-12-2025
  • CYBN 08-13-2025
  • Dividend Yield
  • CRBU N/A
  • CYBN N/A
  • EPS Growth
  • CRBU N/A
  • CYBN N/A
  • EPS
  • CRBU N/A
  • CYBN N/A
  • Revenue
  • CRBU $9,121,000.00
  • CYBN N/A
  • Revenue This Year
  • CRBU $9.23
  • CYBN N/A
  • Revenue Next Year
  • CRBU N/A
  • CYBN N/A
  • P/E Ratio
  • CRBU N/A
  • CYBN N/A
  • Revenue Growth
  • CRBU N/A
  • CYBN N/A
  • 52 Week Low
  • CRBU $0.66
  • CYBN $4.81
  • 52 Week High
  • CRBU $3.00
  • CYBN $13.88
  • Technical
  • Relative Strength Index (RSI)
  • CRBU 56.96
  • CYBN 55.26
  • Support Level
  • CRBU $1.80
  • CYBN $6.36
  • Resistance Level
  • CRBU $2.16
  • CYBN $7.88
  • Average True Range (ATR)
  • CRBU 0.14
  • CYBN 0.37
  • MACD
  • CRBU 0.00
  • CYBN 0.08
  • Stochastic Oscillator
  • CRBU 73.28
  • CYBN 86.25

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Share on Social Networks: